Menu Search
Equities

MDxHealth SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0O8G:LSE

MDxHealth SA

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta0.7490
Data delayed at least 20 minutes, as of Dec 15 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

  • Revenue in USD (TTM)103.07m
  • Net income in USD-31.43m
  • Incorporated2003
  • Employees312.00
  • Location
    MDxHealth SACAP Business Center, Rue d'Abhooz 31HERSTAL 4040BelgiumBEL
  • Phone+32 43642070
  • Fax+32 42597875
  • Websitehttps://mdxhealth.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		MDXH:NAQ since
announced		Transaction
value
Exosome Diagnostics IncDeal completed05 Aug 202505 Aug 2025Deal completed35.63%15.00m
Data delayed at least 15 minutes, as of Mar 03 2026 21:00 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.